Another Recommendation On Wall Street for Wave Life Sciences (WVE). This time with a $61.0000 Share Target Price

Wave Life Sciences Ltd. (NASDAQ:WVE) Logo

Why Has Leerink Partners Given Wave Life Sciences (WVE) a $61.0000 Price Target

Research professionals at Leerink Partners initiated coverage on Wave Life Sciences (WVE) with a key “Buy” rating. The target price per share for WVE is exactly $61.0000. It suggests a possible upside of 27.48 % from firm’s previous close.

Wave Life Sciences Ltd. (NASDAQ:WVE) Ratings Coverage

Among 3 analysts covering Wave Life Sciences (WVE), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Wave Life Sciences has $61 highest and $49 lowest target. $55.33’s average target is 15.63% above currents $47.85 stock price. Wave Life Sciences had 4 analyst reports since June 20, 2018 according to SRatingsIntel. The stock of Wave Life Sciences Ltd. (NASDAQ:WVE) earned “Buy” rating by Leerink Swann on Wednesday, June 20. H.C. Wainwright reinitiated the shares of WVE in report on Monday, July 23 with “Buy” rating.

The stock increased 3.57% or $1.65 during the last trading session, reaching $47.85. About 207,418 shares traded or 109.51% up from the average. Wave Life Sciences Ltd. (WVE) has risen 126.12% since December 2, 2017 and is uptrending. It has outperformed by 110.50% the S&P500.

WAVE Life Sciences Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company has market cap of $1.41 billion. The firm is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It currently has negative earnings. The Company’s advanced therapeutic programs are in HuntingtonÂ’s disease, Duchenne muscular dystrophy , and inflammatory bowel disease (IBD).

More notable recent Wave Life Sciences Ltd. (NASDAQ:WVE) news were published by: Globenewswire.com which released: “Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND – GlobeNewswire” on December 11, 2017, also Globenewswire.com with their article: “Wave Life Sciences to Present at the Jefferies 2018 Healthcare Conference – GlobeNewswire” published on May 31, 2018, Globenewswire.com published: “Wave Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update – GlobeNewswire” on November 09, 2018. More interesting news about Wave Life Sciences Ltd. (NASDAQ:WVE) were released by: Fool.com and their article: “Here’s Why Wave Life Sciences Fell as Much as 12.1% This Morning – Motley Fool” published on April 12, 2017 as well as Seekingalpha.com‘s news article titled: “Pfizer bails on DMD candidate domagrozumab – Seeking Alpha” with publication date: August 30, 2018.

Wave Life Sciences Ltd. (NASDAQ:WVE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.